Related Experiment Video
Updated: May 19, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the
Njira L Lugogo1, Praveen Akuthota2, Kaharu Sumino3
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, United States.
Rationale:
Clinical trials of severe asthma therapies often exclude or underrepresent key patient populations.
Objectives:
To evaluate the effectiveness and safety of tezepelumab in a diverse, real-world US population with severe, uncontrolled asthma (SUA).
Methods:
PASSAGE was a phase 4, multicenter, single-arm, open-label, 12-month study enrolling patients with SUA (≥12 years old), including different phenotypes (blood eosinophil count ≥300 or <300 cells/µL, with or without allergy) and underrepresented populations (Black/African American patients, adolescents, those with SUA with comorbid mild-to-moderate chronic obstructive pulmonary disease, people with a significant smoking history [≥10 pack-years]). The primary outcome was the annualized asthma exacerbation rate (AAER) in the 12 months before (baseline period) and after (treatment period) tezepelumab initiation.
Measurements And Main Results:
Among 286 participants, AAER decreased by 70% (95% CI, 63%-75%) from 2.88 (baseline period) to 0.87 (treatment period) and by 54% to 77% across phenotypes and underrepresented populations. At week 52, least-squares mean pre-bronchodilator FEV1 increased from baseline by 0.122 L (95% CI, 0.07-0.17) overall and by 0.212 L (95% CI, 0.15-0.28) among participants with percent predicted pre-bronchodilator FEV1 ≤80% at baseline. Clinically meaningful improvements in Asthma Control Questionnaire-6, Asthma Impairment and Risk Questionnaire, and St George's Respiratory Questionnaire scores were observed in 51% to 91% of participants across phenotypes and underrepresented populations at week 52. No new safety signals were identified.
Conclusions:
The PASSAGE study of a diverse, real-world US population with SUA treated with tezepelumab demonstrated substantial reductions in asthma exacerbations across phenotypes and underrepresented populations as well as clinically meaningful improvements in lung function, asthma control, and health-related quality of life.
Clinical Trial Registration:
www.clinicaltrials.gov (NCT05329194).
Related Concept Videos
01:13Asthma III: Clinical Manifestations
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:28Asthma I: Introduction
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...